The attribution of unmade claims in order to discredit
The attribution of unmade claims in order to discredit otherwise reasonable posts in order to suppress critical thinking regarding the stock is a round-about way of pumping. Proper analysis of funding mechanisms and time lines is just as critical to predicting the direction of the stock and the company as is the trial results.
I also haven't seen anyone wish the company or the CEO ill on this board. LieHub is a different story but please refrain from painting critical thinking on this board with such a broad and vile brush.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All content of my posts is my opinion and speculation. Do not treat anything I say as fact or actionable investment advice. I participate to challenge my investment thesis from any angle possible. Please do your own due diligence.
Current Positions:
Long CTIX.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
UST's Strategic Move Into Automotive's Future Wake up and smell the coffee, because UST is shaking up the automotive scene. They've just pulled off a major play by grabbing a majority stake in Italdesign. If that doesn't scream the next leap forward for the auto world, I don't know what does. UST isn't just buying a company; it's marrying Italdesign's legendary design...
Continue Reading
Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....
Continue Reading
Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...
Continue Reading
Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...
Continue Reading
DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...
Continue Reading
New Leadership Steers Strategic Growth Just when you thought the subscription game couldn't get more interesting, in steps Janesh Janardhanan. Frost & Sullivan, the big brain of analytics and growth advice, has handed him the reins of their fancy subscriptions portfolio. Janardhanan's job? To pump some muscle into their global growth and ensure their analytics and...
Continue Reading
AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...
Continue Reading
When you dive into the world of laboratory glassware, it might look like it's all pipettes and test tubes, but there's more bubbling under the surface. This market's got its eyes on a neat little climb from $7,630 million in 2026 to a forecasted $9,170 million by 2031. Ain't just speculation—this one's solid muscle growing at a comfortable 4.0% compound annual growth...
Continue Reading
Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...
Continue Reading
Potter Magic Takes Over Warner Bros. World Abu Dhabi Call it a stroke of wizardry or plain savvy business sense, Miral and Warner Bros. Discovery Global Experiences are betting large on Harry Potter with a trio of themed lands at Warner Bros. World Abu Dhabi. Brace yourselves, because this ain't your mother's theme park nostalgia—this is about breathing new life into a...
Continue Reading
Top 5 Most Recently Viewed Articles
ICON PLC Faces Class Action Lawsuit Amid Significant Losses The law firm of Robbins Geller Rudman & Dowd LLP has officially announced that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares have the opportunity to lead a class action lawsuit. This action is for investors who experienced significant financial losses between July 27, 2023, and October 23, 2024. The...
Continue Reading
Recent Executive Stock Transactions In a significant move, Anne Morrison, serving as the Executive Vice President, Chief Administrative Officer, and General Counsel at Essex Property Trust, Inc. (NYSE: ESS), sold shares worth over $800,000. Specifically, she sold 2,571 shares at an average price of $314.79, totaling about $809,325. Investors closely watch insider trading...
Continue Reading
TDb Split Corp. Financial Overview TDb Split Corp. has recently published its annual financial statements for the fiscal year concluding on November 30, 2024. These documents detail the company's performance and are accessible for stakeholders to review. Annual Financial Performance Highlights The management report offers insights into the company's fund performance,...
Continue Reading
Growth of Baltic Horizon Fund's NAV in May 2025 The Baltic Horizon Fund reported an increase in its net asset value (NAV) per unit, which rose to EUR 0.6757 at the close of May 2025. This figure represents a slight gain from the NAV of EUR 0.6740 recorded at the end of April 2025. The fund's overall net asset value reached EUR 97.0 million, up from EUR 96.8 million in the...
Continue Reading
Fractyl Health to Report Second Quarter 2025 Financial Results Fractyl Health, Inc. (Nasdaq: GUTS), a leader in metabolic therapeutics, is set to release its financial results for the second quarter of 2025. The report will be available on August 12, 2025, at 4:30 p.m. ET. This pivotal moment is crucial for stakeholders as the company shares insights into its financial...
Continue Reading